Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Compare

410 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KYMR Analyst Ratings

Strong Buy

20 Buy

1 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Kymera

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KYMR Stock 12 Month Forecast

Average Price Target

$119.17

▲(31.41% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $119.17 with a high forecast of $140.00 and a low forecast of $90.00. The average price target represents a 31.41% change from the last price of $90.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","141":"$141","53.25":"$53.3","82.5":"$82.5","111.75":"$111.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119.16666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$119.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,53.25,82.5,111.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.62,80.5723076923077,85.52461538461539,90.47692307692309,95.42923076923077,100.38153846153847,105.33384615384617,110.28615384615385,115.23846153846154,120.19076923076923,125.14307692307693,130.0953846153846,135.04769230769233,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.62,78.96974358974359,82.31948717948718,85.66923076923077,89.01897435897436,92.36871794871794,95.71846153846154,99.06820512820512,102.41794871794872,105.7676923076923,109.11743589743588,112.46717948717948,115.81692307692308,{"y":119.16666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.62,76.72615384615385,77.8323076923077,78.93846153846154,80.04461538461538,81.15076923076923,82.25692307692307,83.36307692307693,84.46923076923078,85.57538461538462,86.68153846153847,87.78769230769231,88.89384615384616,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.62,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$140.00

Average Price Target$119.17

Lowest Price Target$90.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Biren Amin

Piper Sandler

$125→$140

Buy

54.39%

Upside

Reiterated

02/26/26

Kymera Therapeutics price target raised to $140 from $125 at Piper SandlerKymera Therapeutics price target raised to $140 from $125 at Piper Sandler

Jeet Mukherjee

BTIG

$138

Buy

52.18%

Upside

Reiterated

02/03/26

Kymera Therapeutics: KT-621’s Differentiated Efficacy and Safety Profile Underpins Attractive Risk-Reward in Emerging Oral Atopic Dermatitis Market

Geoff Meacham

Citi

$110

Buy

21.31%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: High Tide (NASDAQ: HITI), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Kymera Therapeutics (NASDAQ: KYMR)

Joseph Catanzaro

Mizuho Securities

―

Buy

―

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)

Eliana Merle

Barclays

$119→$133

Buy

46.67%

Upside

Reiterated

01/27/26

Kymera Therapeutics assumed with an Overweight at BarclaysKymera Therapeutics assumed with an Overweight at Barclays

Tazeen Ahmad

Bank of America Securities

$112

Buy

23.51%

Upside

Reiterated

01/27/26

Bank of America Securities Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

01/15/26

TD Cowen Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

01/06/26

Kymera Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchKymera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Mayank Mamtani

B. Riley Securities

$80→$117

Buy

29.03%

Upside

Reiterated

12/22/25

Kymera Therapeutics price target raised to $117 from $80 at B. RileyKymera Therapeutics price target raised to $117 from $80 at B. Riley

Derek Archila

Wells Fargo

$116

Buy

27.92%

Upside

Reiterated

12/16/25

Kymera Therapeutics (KYMR) Gets a Buy from Wells Fargo

Brian Abrahams

RBC Capital

$70→$103

Buy

13.59%

Upside

Reiterated

12/16/25

RBC Capital Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Alex Thompson CFA

Stifel Nicolaus

$68→$114

Buy

25.72%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Fulcrum Therapeutics (NASDAQ: FULC) and Novan (NASDAQ: NOVN)

Sudan Loganathan

Stephens

$65→$110

Buy

21.31%

Upside

Reiterated

12/11/25

Kymera Therapeutics price target raised to $110 from $65 at StephensKymera Therapeutics price target raised to $110 from $65 at Stephens

Brian Cheng

J.P. Morgan

$70→$125

Buy

37.85%

Upside

Reiterated

12/10/25

Kymera Therapeutics: Promising Phase 1b Trial Results and Competitive Edge Drive Buy Rating

Andrew Fein

H.C. Wainwright

$84→$134

Buy

47.77%

Upside

Reiterated

12/09/25

Kymera Therapeutics' KT-621: Promising Oral Treatment for Atopic Dermatitis and Asthma Expansion Potential

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Biren Amin

Piper Sandler

$125→$140

Buy

54.39%

Upside

Reiterated

02/26/26

Kymera Therapeutics price target raised to $140 from $125 at Piper SandlerKymera Therapeutics price target raised to $140 from $125 at Piper Sandler

Jeet Mukherjee

BTIG

$138

Buy

52.18%

Upside

Reiterated

02/03/26

Kymera Therapeutics: KT-621’s Differentiated Efficacy and Safety Profile Underpins Attractive Risk-Reward in Emerging Oral Atopic Dermatitis Market

Geoff Meacham

Citi

$110

Buy

21.31%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: High Tide (NASDAQ: HITI), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Kymera Therapeutics (NASDAQ: KYMR)

Joseph Catanzaro

Mizuho Securities

―

Buy

―

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)

Eliana Merle

Barclays

$119→$133

Buy

46.67%

Upside

Reiterated

01/27/26

Kymera Therapeutics assumed with an Overweight at BarclaysKymera Therapeutics assumed with an Overweight at Barclays

Tazeen Ahmad

Bank of America Securities

$112

Buy

23.51%

Upside

Reiterated

01/27/26

Bank of America Securities Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

01/15/26

TD Cowen Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

01/06/26

Kymera Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchKymera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Mayank Mamtani

B. Riley Securities

$80→$117

Buy

29.03%

Upside

Reiterated

12/22/25

Kymera Therapeutics price target raised to $117 from $80 at B. RileyKymera Therapeutics price target raised to $117 from $80 at B. Riley

Derek Archila

Wells Fargo

$116

Buy

27.92%

Upside

Reiterated

12/16/25

Kymera Therapeutics (KYMR) Gets a Buy from Wells Fargo

Brian Abrahams

RBC Capital

$70→$103

Buy

13.59%

Upside

Reiterated

12/16/25

RBC Capital Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Alex Thompson CFA

Stifel Nicolaus

$68→$114

Buy

25.72%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Fulcrum Therapeutics (NASDAQ: FULC) and Novan (NASDAQ: NOVN)

Sudan Loganathan

Stephens

$65→$110

Buy

21.31%

Upside

Reiterated

12/11/25

Kymera Therapeutics price target raised to $110 from $65 at StephensKymera Therapeutics price target raised to $110 from $65 at Stephens

Brian Cheng

J.P. Morgan

$70→$125

Buy

37.85%

Upside

Reiterated

12/10/25

Kymera Therapeutics: Promising Phase 1b Trial Results and Competitive Edge Drive Buy Rating

Andrew Fein

H.C. Wainwright

$84→$134

Buy

47.77%

Upside

Reiterated

12/09/25

Kymera Therapeutics' KT-621: Promising Oral Treatment for Atopic Dermatitis and Asthma Expansion Potential

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kymera Therapeutics

3 Months

xxx

Success Rate

7/9 ratings generated profit

Average Return

+25.90%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +25.90% per trade.

1 Year

Jeet MukherjeeBTIG

Success Rate

10/11 ratings generated profit

Average Return

+75.89%

a rating ―

Copying Jeet Mukherjee's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +75.89% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+140.86%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +140.86% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYMR Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KYMR has received 33 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the past 3 months is 119.17.

Each month's total comprises the sum of three months' worth of ratings.

KYMR Financial Forecast

KYMR Earnings Forecast

The previous quarter’s earnings for KYMR were -$0.97.

KYMR Sales Forecast

The previous quarter’s earnings for KYMR were $2.87M.

KYMR Stock Forecast FAQ

What is KYMR’s average 12-month price target, according to analysts?

Based on analyst ratings, Kymera Therapeutics’s 12-month average price target is 119.17.

What is KYMR’s upside potential, based on the analysts’ average price target?

Kymera Therapeutics has 31.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KYMR a Buy, Sell or Hold?

Kymera Therapeutics has a consensus rating of Strong Buy which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.

What is Kymera Therapeutics’s price target?

The average price target for Kymera Therapeutics is 119.17. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $90.00. The average price target represents 31.41% Increase from the current price of $90.68.

What do analysts say about Kymera Therapeutics?

Kymera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of KYMR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

KYMR Analyst Ratings

KYMR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kymera Therapeutics

KYMR Analyst Recommendation Trends

KYMR Financial Forecast

KYMR Earnings Forecast

KYMR Sales Forecast

KYMR Stock Forecast FAQ

Detailed List of Analyst Forecasts